R/S-普萘洛尔的手性吸收动力学研究

目的：采用蛋白质组学研究策略,研究R/S-普萘洛尔（Propranolol,PRO）的手性吸收动力学特征,建立其差异蛋白质图谱。方法：体外培养Caco-2细胞并使之在培养瓶底部融合达80%以上;将含160μmol/L的R-PRO和S-PRO的细胞培养液分别加入到培养瓶中,在培养箱中静置培养4 h;吸弃药液,用刮除法收集培养瓶中的Caco-2细胞,细胞全蛋白提取液裂解并收集Caco-2细胞全蛋白,Bradford法蛋白定量;取100μg全蛋白进行双向电泳,建立R-PRO和S-PRO的差异蛋白质图谱;对差异蛋白进行质谱鉴定和生物信息学检索,根据蛋白功能探讨R/S-普萘洛尔的手性吸收动力学特征。结果：R-PRO和S-PRO的蛋白质图谱差异不明显,对其中的明显差异蛋白质点进行质谱检测,成功鉴定到8个蛋白,分别为：GRP78、GRP75、HSP7C、HSP71、Cytokeratin 8、PIP5K、Ran、Prohibition,经生物物信息学检索,这些蛋白的功能主要涉及细胞的应急反应、能量代谢、生长繁殖等,与药物的主动吸收无直接相关。结论：成功建立了R-PRO和S-PRO的差异蛋白质图谱;R-PRO和S-PRO在蛋白质组学方面虽然存在差异,但这些蛋白与药物的主动吸收无直接相关,推测两药在体外的吸收转运无手性差异,与其它方法的研究结果一致。此外,研究中发现的差异蛋白提示,R-PRO和S-PRO在对细胞的新陈代谢方面有差异,可能与两者在体内的系统清除率的差异相关,这有待进一步研究证实。     

二氢吡啶类钙通道阻滞剂及其药物手性研究

人体是一种高度复杂的手性环境.手性药物用于机体后.两对映体与体内的大分子物质结合,呈现作用机制和结合力的差别,从而导致手性药物的体内立体选择性特征,产生药理学上的差别.二氢吡啶类钙通道阻滞剂具有舒张血管等重要作用,在临床上对治疗高血压等心脑血管痰病具有很好的临床应用价值.本文就以手性药物和钙通道阻滞剂的药效学立体选择性作一综述.     

应用蛋白质组学技术筛选胃癌耐药相关蛋白质

胃癌多药耐药性是临床胃癌化疗失败最主要的原因之一,但其分子机制仍然不太清楚.为了寻找新的胃癌耐药相关的蛋白质,揭示胃癌多药耐药的分子机制,以胃癌细胞SGC7901和长春新碱诱导的耐药胃癌细胞SGC7901/VCR为研究对象,应用二维凝胶电泳(two-dimensionalelectrophoresis,2-DE)技术分离两种细胞的总蛋白质,图像分析识别差异表达的蛋白质点,基质辅助激光解吸电离飞行时间质谱(matrix-assistedlaserdesorption/ionizationtimeofflightmassspectrometry,MALDI-TOF-MS)及电喷雾电离串联质谱(electrosprayionizationtandemmassspectrometry,ESI-Q-TOF)对差异表达的蛋白质点进行鉴定,蛋白质印迹和实时RT-PCR验证部分差异蛋白质在两株细胞中的表达水平,反义核酸转染技术分析HSP27(heatshockprotein27,HSP27)高表达与SGC7901/VCR耐药的相关性.得到了分辨率较高、重复性较好的两株细胞系的二维凝胶电泳图谱,质谱分析共鉴定了24个差异蛋白质点,蛋白质印迹和实时RT-PCR验证了部分差异蛋白的表达水平,反义寡核苷酸抑制HSP27表达能增加SGC7901/VCR对长春新碱的敏感性.研究结果不仅提示这些差异蛋白质如HSP27,Sorcin等可能与胃癌的多药耐药相关,而且为揭示胃癌细胞的多药耐药性产生机制提供了线索.     

MPTP慢性帕金森病小鼠纹状体差异蛋白质的研究

目的分离、鉴定MPTP诱导慢性帕金森病模型小鼠纹状体差异表达的蛋白质,对MPTP慢性PD动物模型的特异性蛋白质组进行初步探讨,为PD的发病机制提供一定的蛋白质组学依据。方法成功建立MPTP诱导慢性帕金森病小鼠模型,提取模型组和对照组小鼠脑纹状体蛋白质,分别以固相pH梯度等电聚焦为第一向,SDS-PAGE垂直电泳为第二向进行2-DE。图像分析软件PDQUEST8.0分析电泳图谱找出差异表达蛋白,运用MALDI-TOF MS质谱鉴定;其肽质量指纹图（PMF）经MS Fit检索。结果比较MPTP诱导慢性PD模型小鼠和正常对照小鼠纹状体二向电泳图,发现12个蛋白表达异常,最终鉴定出其中4个蛋白质：线粒体裂殖调节因子1（mitochondrial fission regulator 1）、类泛素样蛋白3前体（ubiquitin-like protein 3 precursor）表达下调;S100蛋白A10（proteinS100-A10）、Lin-7 homolog B为新出现点。结论初步鉴定出MPTP慢性PD模型小鼠纹状体部分差异表达蛋白,所发现4个表达异常的蛋白质与帕金森病线粒体的损伤和兴奋性神经毒性密切相关,与PD的发病机制相符,为深入研究帕金森病病理机制奠定了基础。     

外源H2S影响黄瓜幼苗响应高盐胁迫的蛋白质组学分析

为了阐明外源H₂S对高盐胁迫下黄瓜蛋白质表达的影响,以盐敏感型黄瓜栽培种‘春夏秋王’为材料,通过双向电泳（2 DE）技术分离叶片总蛋白质,采用基质辅助激光解析飞行时间串联质谱（MALDI TOF/TOF MS）技术对差异表达蛋白质进行质谱鉴定,并利用NCBI及SwissProt数据库检索进行差异表达蛋白质功能注释和代谢通路分析。结果表明：(1) 共检测到约2 490个蛋白质,其中蛋白质表达差异在1.5倍以上且差异显著(P<0.05)的有45个,其中有24个蛋白质表达上调,21个蛋白质表达下调。(2) 成功鉴定蛋白质26个,这些蛋白质参与了光合作用（26.92%）、蛋白质代谢（23.08%）、能量与碳水化合物代谢（11.54%）、氨基酸生物合成（11.54%）、细胞结构相关蛋白（7.69%）、抗氧化作用（3.85%）、信号转导（3.85%）及未知功能蛋白（11.54%）。(3) GO注释表明差异表达的蛋白质分子功能主要以蛋白质结合与水解酶活性为主,生物学过程涉及应激反应、有机物代谢过程、胁迫响应和细胞分化等,细胞组成集中分布在细胞部分和一些胞内细胞器。KEGG代谢通路分析表明,差异表达蛋白质主要参与了肌动蛋白细胞骨架调控、细胞凋亡、碳代谢和光和调控等代谢途径。研究表明,外源H₂S诱导了高盐胁迫下黄瓜叶片蛋白质的差异表达,为后续探索外源H₂S对黄瓜的抗盐分子机制研究提供了理论依据。     

应用蛋白质组学和RNAi技术筛选鼻咽癌细胞中p53功能相关蛋白质

为了阐明鼻咽癌中高表达的p53蛋白聚集与失活的机制,高通量地检测与p53功能相关的蛋白质,首先采用RNA干扰(RNAi)技术稳定沉默鼻咽癌细胞系CNE2的p53基因表达,然后用蛋白质组技术研究稳定沉默该基因对鼻咽癌蛋白质表达谱的影响.通过对稳定干扰p53基因后鼻咽癌细胞系CNE2的蛋白质表达谱改变的研究,用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)分析和电喷雾串联质谱(ESI-Q-TOF-MS)验证鉴定了22个差异表达蛋白质.在这些差异表达蛋白质中,有些是已经报道的p53功能相关蛋白质,如热休克蛋白27(HSP27)、异质性胞核核糖核蛋白K(hnRNPK)、14-3-3σ等,其他可能是新的p53功能相关蛋白质,如eIF4B、TPT1、hnRNPH3、SFRS1等.部分差异表达蛋白质如HSP27、14-3-3σ和GRP75经蛋白质印迹分析技术进行了验证,同时pcDNA3.1-FLAG-p53质粒转染CNE2细胞引起了HSP27、14-3-3σ表达下调,GRP75表达上调.在鼻咽癌细胞中鉴定的22个差异表达蛋白质大致可以分为5类,包括信号传导相关蛋白质、分子伴侣、与转录和翻译相关蛋白质、代谢相关蛋白和细胞结构相关蛋白质,涉及到细胞周期的调控、分子基因表达调控、细胞黏附、细胞代谢等众多事件,它们可能作为p53功能相关蛋白质,为阐明鼻咽癌中p53蛋白聚集及失活的机制提供了重要依据和线索.     

融合细胞株Eahy926与亲本人肺腺癌细胞株A549差异表达蛋白的蛋白质组学分析

融合细胞株Eahy926是人肺腺癌细胞株A549和人脐静脉内皮细胞杂交而成的永生化细胞株,具有血管内皮细胞的特性,已广泛用于内皮细胞相关研究. 本研究应用蛋白质组学技术分析融合细胞株Eahy926与亲本人肺腺癌细胞株A549的蛋白质差异表达,探讨融合细胞生物学特性变化及其机制. 对Eahy926和亲本A549的细胞总蛋白质进行双向凝胶电泳,在PDQuest软件辅助下找出差异表达蛋白质点,经肽质量指纹图谱(peptide mass fingerprinting, PMF) 和串级质谱(tandem mass spectrometry,TMS) 分析,SWISS-PROT数据库检索,成功鉴定出28个差异蛋白,如CATB、CK8、CK18、annexin A2、GRP78、HSP90、HSP60、vimentin等一些与分子伴侣、氧化应激、能量代谢、信号转导等有关,并与肿瘤细胞分裂增殖、分化凋亡、侵袭转移、免疫逃逸以及肿瘤血管生长密切关联的蛋白质. 研究发现,融合细胞株Eahy926和人肺腺癌细胞株A549的蛋白质组表达谱存在明显差异,这将有助于今后进一步探讨肿瘤细胞与内皮细胞的相互作用机制及其融合细胞的特性,筛选肿瘤增殖和转移相关蛋白质及分子标志物,亦可为肿瘤的抗血管生成治疗提供新思路.     

热CO2气腹处理后结肠癌细胞株COLO 205的蛋白组学变化

目的：研究热CO2气腹处理后结肠癌细胞株COLO205的蛋白组学变化,为阐明热CO2气腹对结肠癌细胞的杀伤作用机制提供依据。方法：用热CO2气腹处理结肠癌细胞株COL0205,按有无处理分为处理组与对照组。分别抽提两组细胞的总蛋白质,采用同位素标记的相对和绝对定量（isobaric tags for relative absolute quantitation, iTRAQ）技术标记,液相色谱（LC）分离蛋白质,质谱仪（MS）进行蛋白质鉴定及Western blot检测。结果：共筛选得到18个差异表达的蛋白,其中8个蛋白表达上调,10个蛋白表达下调。Western blot显示热休克蛋白HSP70在细胞表达明显高于对照组（P〈0．01）;蛋白Myosin-9的表达量在处理后显著下降。结论：热CO2气腹处理后结肠癌细胞株COL0205的蛋白组学发生差异性变化。     

基于iTRAQ技术分析五倍子作用白念珠菌后的差异蛋白表达

为了探讨五倍子抗白念珠菌的作用机制,提取4 μg/mL五倍子提取液作用后的白念珠菌（SC5314）总蛋白,采用同位素标记相对和绝对定量（isobaric tags for relative and absolute quantitation,iTRAQ）蛋白质组学技术、液相色谱串联质谱（LC-MS/MS）技术分析和鉴定差异表达的蛋白质,并对差异表达蛋白进行生物信息学分析。经LC-MS/MS鉴定出3 721种蛋白质,其中,差异表达蛋白104种,包括57种表达上调蛋白和47种表达下调蛋白。通过生物信息学分析发现,上述差异蛋白参与了氧化还原反应、过氧化氢分解代谢以及能量代谢等生物学过程。研究表明,五倍子抗白念珠菌的作用机制可能是通过抑制氧化磷酸化,进而影响菌体能量代谢和物质生成,最终导致细胞结构与功能的改变。     

热CO2气腹处理后结肠癌细胞株COLO 205的蛋白组学变化

目的:研究热CO₂气腹处理后结肠癌细胞株COLO 205的蛋白组学变化,为阐明热CO₂气腹对结肠癌细胞的杀伤作用机制提供依据。方法:用热CO₂气腹处理结肠癌细胞株COLO 205,按有无处理分为处理组与对照组。分别抽提两组细胞的总蛋白质,采用同位素标记的相对和绝对定量（isobaric tags for relative absolute quantitation,iTRAQ）技术标记,液相色谱（LC）分离蛋白质,质谱仪（MS）进行蛋白质鉴定及Western b1ot检测。结果:共筛选得到18个差异表达的蛋白,其中8个蛋白表达上调,10个蛋白表达下调。Western blot显示热休克蛋白HSP70在细胞表达明显高于对照组（P<0.01）;蛋白Myosin-9的表达量在处理后显著下降。结论:热CO₂气腹处理后结肠癌细胞株COLO 205的蛋白组学发生差异性变化。     

免疫共沉淀结合微流控芯片技术筛选GBLP相互作用蛋白

为了进一步阐明G蛋白β亚基2样1蛋白（guanine nucleotide-binding protein subunit beta 2-like 1,GBLP）在普萘洛尔（propranolol,PRO）生物学效应发生机制中的作用,采用免疫共沉淀法结合液相色谱-芯片-离子阱串联质谱（HPLC-CHIP-IT-MS/MS）系统筛选并鉴定人脐静脉内皮细胞（human umbilical vein endothelial cell,HUVEC）中的GBLP相互作用蛋白.结果表明,有7种蛋白与GBLP存在相互作用,分别为酪蛋白α-S1、酪蛋白α-S2、β酪蛋白、桥粒芯蛋白1前体、α-烯醇化酶、果糖二磷酸醛缩酶C、硫氧还原蛋白过氧化物酶2.这些蛋白的生物信息学检索结果提示,GBLP可能参与了细胞的能量代谢调节和抗氧化机制,与普萘洛尔的生物学效应发生机制密切相关.     

The role of branching glycan of human alpha1-acid glycoprotein in enantioselective binding to basic drugs as studied by capillary electrophoresis

The role of the branching glycan structure of human alpha1-acid glycoprotein (AGP) in the interaction with basic drugs was investigated in terms of enantioselectivity in binding ability. AGP was separated by concanavalin A lectin affinity chromatography into two subfractions, the unretained AGP (UR-AGP) which has no biantennary glycan chain and the retained AGP (R-AGP) which possesses biantennary oligosaccharide chain(s). The unbound concentrations of propranolol (PRO) enantiomers and verapamil (VER) enantiomers in UR-AGP solution and R-AGP solution were determined by high-performance frontal analysis combined with capillary electrophoresis. It was found that (S)-PRO is bound to UR-AGP and R-AGP more strongly than (R)-PRO, whereas the reverse applies to VER enantiomers, and that such enantioselectivity is common to these proteins. This suggests that the branching type of glycan chains of AGP does not play significant role in the chiral recognition in binding these basic drugs.     

Effect of sialic acid residues of human α1-acid glycoprotein on stereoselectivity in basic drug-protein binding

The function of sialic acid groups at the terminal of sugar chains of human α₁-acid glycoprotein (AGP) was investigated with respect to chiral discrimination between optical isomers of basic drugs, using high-performance capillary electrophoresis/frontal analysis (HPCE/FA), a novel analytical method developed for the determination of unbound drug concentration with ultramicrosample volume (100–200 nl). Native human AGP and desialylated AGP were used as test proteins, and propranolol (PRO) and verapamil (VER) were used as model drugs. The unbound concentration of (S)-VER was 1.31 times higher than that of (R)-VER in native AGP solution. This selectivity was not affected by desialylation. Further, enzymatic elimination of galactose residues, which neighbored sialic acid groups, did not change the binding of either isomer of VER. On the other hand, the unbound concentration of (R)-PRO was 1.27 times higher than that of (S)-PRO in native AGP solution. Desialylation caused the unbound concentration of (S)-PRO to rise to the same level of (R)-PRO, resulting in loss of enantioselectivity. Thus, it follows that sialic acid groups of AGP, as a whole, are not responsible for chiral recognition between enantiomers of VER but are involved in enantioselectivity toward the isomers of PRO. Chirality 9:291–296, 1997. © 1997 Wiley-Liss, Inc.     

Biological significance of the enantiomeric purity of drugs

The knowledge that enantiomers of chiral compounds may differ widely in biological activity, qualitatively as well as quantitatively, is not new. Nevertheless most of the pharmacological data available to date on chiral drugs are obtained from experiments with racemates which assume that the biological activity generally resides in one of the enantiomers. With the advancements made in stereospecific synthesis and stereoselective analysis of drugs pharmacologists are now offered new possibilities to explore the steric aspects of drug action. This survey will discuss pharmacological data obtained with enantiomer pairs of phenylethylamine derivatives which interact with adrenergic mechanisms. The degree of resolution is seldom specified in published work on stereoselectivity of drugs. In a recent study from our laboratory the enantiomers of the β₂-adrenoceptor agonist formoterol and their diastereomers have been evaluated. We found that the (R;R)-enantiomer was by far the most potent. However, the relative potencies obtained for the (R;S)-, (S;R), and (S;S)- isomers were critically dependent on the degree of enantiomeric purity. It is concluded that the certainty of potency ratios observed for chiral drugs is limited by the enantiomeric purity and by unspecific effects of the least active enantiomer at very high concentrations. © 1993 Wiley-Liss, Inc.     

Electrically Assisted Liquid‐Phase Microextraction Combined With Capillary Electrophoresis for Quantification of Propranolol Enantiomers in Human Body Fluids

In this study, electromembrane extraction (EME) combined with cyclodextrin (CD)‐modified capillary electrophoresis (CE) was applied for the extraction, separation, and quantification of propranolol (PRO) enantiomers from biological samples. The PRO enantiomers were extracted from aqueous donor solutions, through a supported liquid membrane (SLM) consisting of 2‐nitrophenyl octyl ether (NPOE) impregnated on the wall of the hollow fiber, and into a 20‐μL acidic aqueous acceptor solution into the lumen of hollow fiber. Important parameters affecting EME efficiency such as extraction voltage, extraction time, pH of the donor and acceptor solutions were optimized using a Box‐Behnken design (BBD). Then, under these optimized conditions, the acceptor solution was analyzed using an optimized CD‐modified CE. Several types of CD were evaluated and best results were obtained using a fused‐silica capillary with ammonium acetate (80 mM, pH 2.5) containing 8 mM hydroxypropyl‐β‐CD as a chiral selector, applied voltage of 18 kV, and temperature of 20°C. The relative recoveries were obtained in the range of 78–95%. Finally, the performance of the present method was evaluated for the extraction and determination of PRO enantiomers in real biological samples. Chirality 26:260–267, 2014. © 2014 Wiley Periodicals, Inc.     

Analysis of enantiomers of chiral phenethylamine drugs by capillary gas chromatography/mass spectrometry/flame-ionization detection and pre-column chiral derivatization

Several important chiral phenethylamine agents such as mexiletine, fenfluramine, amphetamine, methamphetamine and N-n-propylamphetamine show stereoselective disposition in humans and large differences in therapeutic relevance and toxicity. To analyze the enantiomers of chiral amine drugs, stereoselective methods were developed to separate those enantiomers on an achiral capillary gas chromatography by pre-column chiral derivatization with S-(-)-N-(fluoroacyl)-prolyl chloride. The stereoselectivity and sensitivity can be improved by chiral derivatization. The methods established offer enantioselective, simple, flexible and economic approaches for the analysis of chiral amine drug enantiomers in biological fluids. The methods have been used to determine S-(+)-methamphetamine in human forensic samples and to analyze enantiomers of amphetamine and fenfluramine in rat liver microsomes.     

Implications of chirality and geometric isomerism in some psychoactive drugs and their metabolites

Many drugs contain a chiral centre, or such a centre is introduced during metabolism of the drug in man and in animals. If a single chiral centre is present, the drug will normally exist as a mixture of two enantiomers, of which one may have quite different pharmacologic and/or toxic effects than the other. Chiral drugs that are used in psychiatry, and some other pharmacologically related drugs are identified, and the implications of the presence of one or two chiral centres in these drugs are discussed. Differences in pharmacologic properties of drug and metabolite enantiomers are identified and discussed. Also reviewed are the properties of some drugs used in psychiatry that both are chiral and display geometric isomerism.     

Study on the metabolic mechanism of chiral inversion of S-mandelic acid in vitro

Mandelic acid (MA) is generally used as a biological indicator of occupational exposure to styrene, which is classified as a class of hazardous environmental pollutants. It was found to undergo one-directional chiral inversion (S-MA to R-MA) in Wistar and Sprague-Dawley rats in vivo. This study was aimed to explore the metabolic mechanism of chiral inversion of S-MA in vitro. S-MA was converted to R-MA in rat hepatocytes, whereas MA enantiomers remained unchanged in acidic and neutral phosphate buffers, HepG2 cells, and intestinal flora. In addition, the synthesized S-MA-CoA thioester was rapidly racemized and hydrolyzed to R-MA by rat liver homogenate and S9, cytosolic and mitochondrial fractions. The data suggest that chiral inversion of S-MA may involve the hydrolysis of S-MA-CoA, and its metabolic mechanism could be the same as that of 2-arylpropionic acid (2-APA) drugs.     

Systematic identification of the HSP90 candidate regulated proteome

HSP90 is a central player in the folding and maturation of many proteins. More than two hundred HSP90 clients have been identified by classical biochemical techniques including important signaling proteins with high relevance to human cancer pathways. HSP90 inhibition has thus become an attractive therapeutic concept and multiple molecules are currently in clinical trials. It is therefore of fundamental biological and medical importance to identify, ideally, all HSP90 clients and HSP90 regulated proteins. To this end, we have taken a global and a chemical proteomic approach in geldanamycin treated cancer cell lines using stable isotope labeling with amino acids in cell culture and quantitative mass spectrometry. We identified >6200 proteins in four different human cell lines and ~1600 proteins showed significant regulation upon drug treatment. Gene ontology and pathway/network analysis revealed common and cell-type specific regulatory effects with strong connections to unfolded protein binding and protein kinase activity. Of the 288 identified protein kinases, 98 were geldanamycin treatment including >50 kinases not formerly known to be regulated by HSP90. Protein turn-over measurements using pulsed stable isotope labeling with amino acids in cell culture showed that protein down-regulation by HSP90 inhibition correlates with protein half-life in many cases. Protein kinases show significantly shorter half lives than other proteins highlighting both challenges and opportunities for HSP90 inhibition in cancer therapy. The proteomic responses of the HSP90 drugs geldanamycin and PU-H71 were highly similar suggesting that both drugs work by similar molecular mechanisms. Using HSP90 immunoprecipitation, we validated several kinases (AXL, DDR1, TRIO) and other signaling proteins (BIRC6, ISG15, FLII), as novel clients of HSP90. Taken together, our study broadly defines the cellular proteome response to HSP90 inhibition and provides a rich resource for further investigation relevant for the treatment of cancer.